Mineralys Therapeutics, (MLYS) Institutional Ownership
Track institutional investors, ownership changes, and 13F filings.
Ownership Summary
Total Institutions
107
Total Shares Held
45.96M
Total Value
$565.48M
Institutional Holding %
91.99%
Ownership Distribution
Top 5 Holders
Top Institutional Holders (as of Dec 31, 2024)
| Institution | Shares | Ownership % | Value |
|---|---|---|---|
| CATALYS PACIFIC | 8.64M | 17.30% | $106.41M |
| SAMSARA BIOCAPITAL | 5.07M | 10.16% | $62.47M |
| RA | 4.85M | 9.71% | $59.72M |
| TCG CROSSOVER | 2.47M | 4.94% | $30.41M |
| BlackRock | 2.14M | 4.28% | $26.33M |
| SR ONE | 2.02M | 4.04% | $24.83M |
| FRANKLIN RESOURCES | 1.75M | 3.49% | $21.49M |
| ORBIMED | 1.61M | 3.23% | $19.84M |
| LAURION | 1.41M | 2.83% | $17.39M |
| ADAMS STREET | 1.13M | 2.26% | $13.91M |
Recent Insider Trading
| Insider | Title | Transaction | Shares | Value | Date |
|---|---|---|---|---|---|
| Rodman David Malcom | Chief Medical Officer | M-Exempt | 1.61K | $1.73K | Apr 01, 2025 |
| Rodman David Malcom | Chief Medical Officer | S-Sale | 30.57K | $458.54K | Apr 01, 2025 |
| Rodman David Malcom | Chief Medical Officer | S-Sale | 2.79K | $44.72K | Apr 01, 2025 |
| Rodman David Malcom | Chief Medical Officer | S-Sale | 22.41K | $375.75K | Apr 01, 2025 |
| Rodman David Malcom | Chief Medical Officer | M-Exempt | 1.61K | $1.73K | Apr 01, 2025 |
| Samsara Biocapital Gp, Llc | 10 Percent Owner | P-Purchase | 600.00K | $8.10M | Mar 13, 2025 |
| Akkaraju Srinivas | Director | P-Purchase | 600.00K | $8.10M | Mar 13, 2025 |
| Ra Capital Management, L.P. | Director | P-Purchase | 1.30M | $17.50M | Mar 13, 2025 |
| Rodman David Malcom | Chief Medical Officer | M-Exempt | 6.35K | $6.86K | Mar 12, 2025 |
| Rodman David Malcom | Chief Medical Officer | M-Exempt | 6.35K | $6.86K | Mar 12, 2025 |
Recent Position Changes
| Institution | Shares Changed | % Change | Date |
|---|---|---|---|
| MILLENNIUM | +1.00M | +1015.81% | Feb 14, 2025 |
| INTEGRAL HEALTH ASSET | +519.00K | +145.79% | Feb 14, 2025 |
| ADAMS STREET | -402.85K | -26.28% | Feb 14, 2025 |
| STEMPOINT | +400.10K | +100.00% | Feb 14, 2025 |
| ORBIMED | -391.30K | -19.54% | Feb 14, 2025 |
| JENNISON | +385.73K | +55.40% | Jan 24, 2025 |
| CANDRIAM S.C.A. | +305.27K | +100.00% | Feb 07, 2025 |
| IKARIAN | +152.39K | +84.66% | Feb 14, 2025 |
| ADAR1 | +112.14K | +15.37% | Feb 13, 2025 |
| +89.53K | +100.00% | Feb 14, 2025 |
Recent Ownership Filings
4
Form 4 - Statement of changes in beneficial ownership of securities
Apr 03, 2025
144
Form 144 - Report of proposed sale of securities
Apr 01, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Mar 17, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Mar 17, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Mar 17, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Mar 13, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 24, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 24, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 24, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 24, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 24, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 24, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 24, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 24, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 24, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 24, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 13, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Jan 15, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Jan 15, 2025
4
Form 4 - Statement of changes in beneficial ownership of securities
Jan 15, 2025
Related Metrics
Explore detailed financial metrics and analysis for MLYS.